Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus QUARZAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus QUARZAN.
CANTIL vs QUARZAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Quarzan (clidinium bromide) is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing gastrointestinal motility and secretion.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
5 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 10-14 hours; allows twice-daily dosing with steady state reached in 2-3 days.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Primarily renal excretion of unchanged drug (50-70%) and its active metabolite; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Anticholinergic / Antispasmodic
Antispasmodic